This invention provides compounds that are antagonists of melanin concentrating
hormone receptor-1 (MCH-R1). The compounds are represented by formula I:
##STR1##
where m is zero or one, n is zero to two, Y is oxygen or -N(R9)-,
R1, R2, R3, R4, R5, R9
and Ring A are defined in the specification. Coumarin and quinolone compounds
where R1 and R2 together form a fused benzo ring are preferred.
The invention also provides compounds of formula VI where the coumarin moiety is
replaced by a quinazolinone ring. The compounds are useful for treating MCH-R1-related
disorders, particularly overweight conditions including obesity.
